PDF(Pubmed)
Abstract：
UNASSIGNED: Myosin light chain plays a vital regulatory function in a large-scale cellular physiological procedure, however, the role of myosin light chain 5 (MYL5) in breast cancer has not been reported. In this study, we aimed to elucidate the effects of MYL5 on clinical prognosis and immune cell infiltration, and further explore the potential mechanism in breast cancer patients.
UNASSIGNED: In this study, we first explored the expression pattern and prognostic value of MYL5 in breast cancer across multiple databases, including Oncomine, TCGA, GTEx, GEPIA2, PrognoScan, and Kaplan-Meier Plotter. The correlations of MYL5 expression with immune cell infiltration and associational gene markers in breast cancer were analyzed by using the TIMER, TIMER2.0, and TISIDB databases. The enrichment and prognosis analysis of MYL5-related genes were implemented by using LinkOmics datasets.
UNASSIGNED: We found that there was a low expression of MYL5 in breast cancer than in corresponding normal tissue by analyzing the data from Oncomine and TCGA datasets. Furthermore, research showed the prognosis of the MYL5 high-expression group was better than the low-expression group in breast cancer patients. Furthermore, MYL5 expression is markedly related to the tumor-infiltrating immune cells (TIICs), including cancer-associated fibroblast, B cell, CD8+ T cell, CD4+ T cell, macrophage, neutrophil, and dendritic cell, and related to immune molecules as well as the associated gene markers of TIICs.
UNASSIGNED: MYL5 can serve as a prognostic signature in breast cancer and is associated with immune infiltration. This study first offers a relatively comprehensive understanding of the oncogenic roles of MYL5 for breast cancer.
UNASSIGNED: In this study, we first explored the expression pattern and prognostic value of MYL5 in breast cancer across multiple databases, including Oncomine, TCGA, GTEx, GEPIA2, PrognoScan, and Kaplan-Meier Plotter. The correlations of MYL5 expression with immune cell infiltration and associational gene markers in breast cancer were analyzed by using the TIMER, TIMER2.0, and TISIDB databases. The enrichment and prognosis analysis of MYL5-related genes were implemented by using LinkOmics datasets.
UNASSIGNED: We found that there was a low expression of MYL5 in breast cancer than in corresponding normal tissue by analyzing the data from Oncomine and TCGA datasets. Furthermore, research showed the prognosis of the MYL5 high-expression group was better than the low-expression group in breast cancer patients. Furthermore, MYL5 expression is markedly related to the tumor-infiltrating immune cells (TIICs), including cancer-associated fibroblast, B cell, CD8+ T cell, CD4+ T cell, macrophage, neutrophil, and dendritic cell, and related to immune molecules as well as the associated gene markers of TIICs.
UNASSIGNED: MYL5 can serve as a prognostic signature in breast cancer and is associated with immune infiltration. This study first offers a relatively comprehensive understanding of the oncogenic roles of MYL5 for breast cancer.
摘要：
未经证实：肌球蛋白轻链在大规模的细胞生理过程中起着至关重要的调节功能，然而,肌球蛋白轻链5（MYL5）在乳腺癌中的作用尚未见报道。在这项研究中,我们旨在阐明MYL5对临床预后和免疫细胞浸润的影响，并进一步探讨乳腺癌患者的潜在机制。
未经批准：在这项研究中，我们首先在多个数据库中探索了MYL5在乳腺癌中的表达模式和预后价值，包括Oncomine,TCGA,GTEx,GEPIA2,PrognoScan,和Kaplan-Meier绘图仪.应用TIMER分析MYL5表达与乳腺癌免疫细胞浸润及相关基因标志物的相关性,TIMER2.0和TISIDB数据库。使用LinkOmics数据集进行MYL5相关基因的富集和预后分析。
UNASSIGNED：我们通过分析Oncomine和TCGA数据集的数据发现，乳腺癌中MYL5的表达比相应的正常组织低。此外，研究显示MYL5高表达组的乳腺癌患者预后优于低表达组。此外，MYL5表达与肿瘤浸润免疫细胞（TIIC）显着相关，包括癌症相关的成纤维细胞，B细胞,CD8+T细胞，CD4+T细胞,巨噬细胞,中性粒细胞,和树突状细胞，并与免疫分子以及TIIC的相关基因标记有关。
UNASSIGNED：MYL5可以作为乳腺癌的预后标志，并与免疫浸润有关。这项研究首先提供了对MYL5在乳腺癌中的致癌作用的相对全面的了解。
未经批准：在这项研究中，
UNASSIGNED：我们通过分析Oncomine和TCGA数据集的数据发现，乳腺癌中MYL5的表达比相应的正常组织低。
UNASSIGNED：MYL5可以作为乳腺癌的预后标志，并与免疫浸润有关。
